Research programme: phytocannabinoid-based therapeutics - India Globalization Capital

Drug Profile

Research programme: phytocannabinoid-based therapeutics - India Globalization Capital

Alternative Names: IGC-501; IGC-503; IGC-504; IGC-506; IGC-AD1

Latest Information Update: 20 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator India Globalization Capital
  • Class Analgesics; Antidementias; Cannabinoids
  • Mechanism of Action Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators; G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cachexia; Cancer pain; Eating disorders; Epilepsy; Neuropathic pain; Post-traumatic stress disorders

Most Recent Events

  • 12 Jun 2017 Preclinical trials in Alzheimer's disease in USA (unspecified route) before June 2017
  • 12 Jun 2017 India Globalization Capital in-licenses US patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease” from University of South Florida
  • 11 Apr 2017 Preclinical trials in Cachexia in USA (unspecified route) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top